医学
Blinatumoab公司
内科学
食品药品监督管理局
耐火材料(行星科学)
年轻人
肿瘤科
药品
淋巴细胞白血病
儿科
白血病
急性淋巴细胞白血病
重症监护医学
免疫学
药理学
物理
天体生物学
作者
Stephanie Si Lim,Stephen Grupp,Amanda M. DiNofia
摘要
The treatment landscape for cancer therapy has changed drastically over the past decade. Tisagenlecleucel, the first genetically engineered adoptive cellular therapy approved by the United States Food and Drug Administration, has revolutionized this field by demonstrating impressive clinical success in children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). Now 3 years since its approval, we have gained a deeper understanding on the basic immunobiology and clinical efficacy of this drug. This review will provide an updated summary of tisagenlecleucel in childhood and young adults with r/r B-ALL, common side effects and their associated management strategies, as well as barriers that remain to be addressed in order to realize the maximum potential of this drug.
科研通智能强力驱动
Strongly Powered by AbleSci AI